Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis
Summary
This summary is machine-generated.Aggressive systemic mastocytosis treatment remains challenging. Cyclosporin combined with low-dose methylprednisolone showed a positive response in a patient, suggesting a potential new therapy.
Area Of Science
- Hematology
- Immunology
- Dermatology
Background
- Aggressive systemic mastocytosis lacks effective treatments.
- Mast cell proliferation characterizes this condition.
Purpose Of The Study
- To evaluate cyclosporin and low-dose methylprednisolone for aggressive systemic mastocytosis.
- To assess treatment effects in a 64-year-old male patient.
Main Methods
- Immunohistochemical analysis of skin and organ biopsies.
- In vitro studies on mast cell activation and histamine release.
- Measurement of mediator levels before and after treatment.
Main Results
- Biopsies revealed increased mast cells, with 20-50% tryptase-positive cells.
- Cyclosporin inhibited histamine release from activated mast cells in a dose-dependent manner.
- The patient exhibited a favorable response to cyclosporin and methylprednisolone therapy.
Conclusions
- Cyclosporin and low-dose methylprednisolone demonstrate potential as a treatment for aggressive systemic mastocytosis.
- This combination therapy warrants further investigation for managing aggressive systemic mastocytosis.
View abstract on PubMed